I simply want to say that each situation is different. In fact, there are two programs, one of which concerns drugs, and the other medical instruments. The criteria vary somewhat depending on the program.
With regard to breast implants, this file isn't a new one; that's why you're more familiar with the situation than I am. Decisions have been changed depending on what was known about the health risks. Once new studies were published, the department determined that we knew enough about the risks incurred for it to be legitimate to support breast implants under the Special Access Program.
As for drugs intended to treat HIV/AIDS, the situation is somewhat different. In the case you referred to, we were in negotiations with the physicians. We offered access to the clinical trials program so that these drugs were accessible. That is ultimately what was done. The clinical trials made it possible to obtain more information on the subject. Consequently, it may be that it will now be appropriate to use the Special Access Program in the case of those drugs.
In short, we can't draw a direct comparison between these two entities. The point in both cases is to protect public health.